 |
|
 |
|
Ask the NET Expert, May 2022
Featuring Jerome S. Zacks, MD
| |
Ask the NET Expert, CCF’s new website-based program, continues with Jerome S. Zacks, MD, cardiologist, as the featured expert answering questions from the neuroendocrine tumor community during May 2022. Dr. Zacks has extensive experience caring for patients with carcinoid heart disease. He is the founder and Medical Director of the Carcinoid Heart Center, located in New York City. The Center’s patient focus is two-fold: first, on issues related to carcinoid syndrome and its resultant carcinoid heart disease. Second, based on the belief that a healthy heart is important when living with neuroendocrine cancer and all its manifestations and complications, the Carcinoid Heart Center focuses on all the important cardiovascular risk factors, including hypertension, diabetes, lipid disorders, obesity, smoking behavior, homocysteine, cardio-selective C-reactive protein, dietary factors and life-style/exercise habits. Dr. Zacks is also Associate Clinical Professor of Medicine, Cardiology, at the Icahn School of Medicine at Mount Sinai in New York City.
| |
Launched in February 2022, the Ask the NET Expert program gives NET patients and loved ones, as well as people seeking a diagnosis, the unique opportunity to get the expertise of doctors from around the country in all areas of medicine including medical oncology, surgical oncology, endocrinology, radiology, nuclear medicine, gastroenterology, and more via CCF’s website. Each month a different NET expert will answer your questions.
Questions should be general in nature as the physicians cannot answer case-specific questions. Questions can be on any NET-related subject including, but not limited to, diagnosis, biomarkers, pathology reports, clinical trials, and treatments.
We hope to be able to answer every question received but this may not be possible.
We post the questions and responses on our website, but please know your name will not be published.
Dr. Zacks is a co-author of “Diagnosing and Managing Carcinoid Heart Disease in Patients with Neuroendocrine Tumors: An Expert Statement,” published in the Journal of the American College of Cardiology. Given that up to 50 percent of neuroendocrine cancer (carcinoid) patients go on to develop carcinoid heart disease, which is often more life-threatening for patients than the usually slow-growing neuroendocrine tumors, these guidelines are a huge step towards the goal of educating patients and doctors about the current gold standard in diagnosis and treatment.
| |
|
|
|
The Carcinoid Cancer Foundation's educational, awareness and advocacy activities are made possible by your contributions. These crucial activities lead toward early detection, improving the quality of life for cancer survivors, and ultimately to a cure. The Carcinoid Cancer Foundation is a 501(c)(3) nonprofit organization. All contributions to the Carcinoid Cancer Foundation are tax-deductible to the extent allowed by law. Thank you for your support.
|
 |
Carcinoid Cancer Foundation
118 North Bedford Road, Suite 100
Mt. Kisco, NY 10549
Phone: 888.722.3132
Email: carcinoid@carcinoid.org
|
|
|
|
